key: cord-0259156-hpsk9f95 authors: prazuck, t.; Gravier, A.; Pires-Roteira, D.; Theillay, A.; Pallay, S.; Colin, M.; Serreau, R.; Hocqueloux, L.; Cassuto, N. G. title: Evaluation Of A New All In One Sars-Cov-2 Antigen-Detecting Rapid Diagnostic Test And Self-Test: Diagnostic Performance And Usability On Child And Adult Population date: 2021-09-26 journal: nan DOI: 10.1101/2021.09.14.21263403 sha: 162dd3e246a096cde784ee839e324d69124553d0 doc_id: 259156 cord_uid: hpsk9f95 The control of the COVID-19 epidemics has been one of top global health priorities for the last eighteen months. To that end, more reliable and easy-to-use diagnostic tests are necessary. Young children are still not eligible to vaccination and it is important to find a way to easily test this key population regularly. With that in mind, we evaluated a new innovative easy two-step self-test named COVID-VIRO ALL IN developed by AAZ that uses a sampling nasal sponge instead of a classic nasal swab. Mirroring the previous study conducted on the first generation of COVID-VIRO antigenic self-test, we first performed a multicentre, prospective study on 124 adults and children, in a point-of-care setting. Sensitivity, specificity and overall acceptance of the COVID-VIRO ALL IN antigen self-test compared to RT-PCR on nasopharyngeal samples were evaluated at 93.02%, 100% and 97,5%, respectively. We then performed a multicentre, prospective, usability study to evaluate the ease of use of COVID-VIRO ALL IN in real life on 68 laypersons, all adults. Globally, 99% of them considered the instructions material good, 98% executed the procedure well, and all of them interpreted the results correctly. The usability was then specifically investigated on 40 children and teenagers participants, comparing both COVID-VIRO first generation and the new COVID-VIRO ALL IN. All of them found COVID-VIRO ALL IN much easier to use and much more comfortable. For young children, the COVID-VIRO ALL IN self-test appears to be safer (less risk of trauma compare to nasal swabs and no liquid exposure) easier to use than classic COVID self-tests and giving immediate result which is not the case for RT-PCR done on saliva samples (currently done in routine for kids in French schools). It could be an adapted tool for future mass screening campaigns in schools or at home under adult supervision for kids from the age of 3. 44 COVID-19 is an infectious respiratory disease caused by the SARS-CoV-2 virus. As of now, 45 this disease which started in Wuhan, China in 2019, has spread worldwide and has been 46 acknowledged as a pandemic disease on 11 March 2020 by the World Health Organization 47 (WHO). 1 COVID-19 is characterised by pneumonia and upper/lower respiratory tract 48 infection. Symptoms appear after an average incubation period of 5.2 days, the most 49 common being fever, cough and fatigue, but also headache, sore throat and even acute 50 respiratory distress syndrome leading to respiratory failure. can also take several days before acquisition. Finally, although nasopharyngeal sampling is 58 generally safe, this procedure is not exempt of any physical nor psychological risk, especially 59 if performed in a repetitive and intensive manner. The FDA has already approved several antigen home tests and the French health authority 72 (Haute autorité de Santé, HAS) has defined the minimal performance requirements for these 73 tests with an emphasis on the necessity of conducting real life studies. The study was evaluated and approved by the French ethics committee (Comité de 89 Protection des Personnes Nord-Ouest IV) in October 2020 and was notified to the French 90 data protection authority. This study was conducted in accordance with the Declaration of 91 Helsinki. This implies that all participants provided written informed consent before 92 undergoing any study-specific procedure. Two different study settings were used, one for the 93 performance study on adults and children and one for the usability/practicability study on 94 adults. Usability/practicability was also assessed for children, while comparing COVID-VIRO 95 ALL IN ® and COVID-VIRO ® . Consent from parents or legal representative was collected for 96 all non-adult participants. 97 The performance study was set in the two COVID units of the Centre Hospitalier Régional 98 d'Orléans: La Madeleine Hospital and La Source Hospital. The inclusion criteria for the 99 performance study were the following: minors (ages from 5 to 17 years old) with the 100 agreement of the legal representative or adults volunteers (> 18 years old), harboring mild to 101 moderate symptoms (headache, fatigue, fever, sore throat, aches and pains, loss of smell 102 and taste etc.), for less than 7 days and not requiring immediate hospitalization. The non-103 inclusion criteria were: hospitalised patients, symptomatic patients with symptoms duration > 104 7 days, asymptomatic patients or asymptomatic contact with a known case. 105 Regarding the usability study, the adult volunteers who participated were patients of a 106 medical analysis laboratory (Drouot laboratory, Paris) while children participants were 107 recruited from our infectious diseases department (Orléans Regional Hospital). No specific 108 inclusion/non-inclusion criteria were applied. CoV-2 antigen is present in the sample, no colour will appear on the test line. The control line 122 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.14.21263403 doi: medRxiv preprint 2.3.2 Usability study on adults (>18 years old) 149 Each participant was asked to consult the instructions for use (written, French language only, 151 available in Figure 1 ) in full before carrying out the self-test. Each person was then asked to 152 collect a nasal sample in both nostrils with the nasal sponge included in the device, dip the 153 device back into the diluent pad, pierce the buffer capsule by pushing the device in the 154 support, and wait for the valid result ( Figure 1 ). Each participant was asked to comment on 155 the different steps of the self-test on a questionnaire ( Table 1 ). The person performing the 156 test was supervised by an observer (laboratory staff, nurse or doctor) who gave an a 157 posteriori assessment of the performance of the various steps by filling in an evaluation form 158 for each participant (Table 1) . 159 The usability study also included a test result interpretation exercise during which the 161 observer instructed the participant to randomly select 1 of 4 contrived self-tests (1 negative, 2 162 positive and 1 invalid), read it and give his/her interpretation of the result. The participant 163 interpretation as well as his/her opinion on the ease of interpretation was collected on a 164 questionnaire (Table 2) . 165 In the same fashion as the adults, each participant was asked to comment on the different 167 steps of the COVID-VIRO ALL IN ® and COVID-VIRO ® self-tests on a questionnaire (Table 3) . 168 For 12-15 years old participants, the test was supervised by an observer (laboratory staff, 169 nurse or doctor) who gave an a posteriori assessment of the performance of the various 170 steps by filling in an evaluation form for each participant (Table 3 ). The test was directly 171 performed by the parent/legal representative on 3-11 years old participants. The usability 172 study also included a test result interpretation exercise during which the observer instructed 173 the participant to randomly select 1 of 4 contrived self-tests (1 negative, 2 positive and 1 174 invalid, Figure 2 ), read it and give his/her interpretation of the result. The participant 175 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.14.21263403 doi: medRxiv preprint interpretation as well as his/her opinion on the ease of interpretation was collected on a 176 questionnaire (Table 4 ). The participant was then asked his preferences concerning COVID-177 VIRO ALL IN ® or COVID-VIRO ® (Table 5) Confidence intervals for sensitivity and specificity were obtained with the Wilson score 200 method. 201 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Regarding the quality of the COVID-VIRO ALL IN ® self-test instructions, all participants but 235 one (98.5%) found the quality of the written instructions to be either good or very good. The 236 last participant chose to respond "bad" to that question. Regarding the ease of execution of 237 the COVID-VIRO ® sample collection (nasal sampling), 100% of the participants found it easy 238 or very easy (16.2% and 83.8% respectively). Likewise, COVID-VIRO ALL IN ® self-test 239 procedures were considered easy or very easy to perform by nearly all the participants 240 (25.0% easy and 73.5% very easy). Only one found them hard to execute. Interestingly, it 241 appeared that it was the same patient that was not satisfied with the written instructions. 242 During the execution of the test, every participant was supervised by a trained professional 243 (physician, nurse or laboratory personnel) and had the opportunity of requesting his/her 244 assistance. Then, the supervisor had to rate the execution quality of the test procedures by 245 the participant. Only 2/68 (2.9%) of the subjects were considered as having poorly executed 246 the test procedures whereas 66 (97.1%) were rated as good or very good (21/68 -30.9% 247 and 45/68 -66.2%, respectively). The most frequent observation was that some test users 248 were repositioning the protective cover on top of the test after sample collection, despite 249 instructions asking to throw it away, making it impossible to carry out the next steps properly. 250 As an interpretation exercise, the subjects were then randomly given one out of four 251 contrived tests and requested to read and interpret its result. Among all participants, 21 252 sorted a negative test, 4 an invalid test and 43 a positive test. Overall, none of the 68 253 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.14.21263403 doi: medRxiv preprint patients misinterpreted the test. Only one patient found the reading and interpreting steps 254 difficult, the majority considering them to be either easy (14.7%) or very easy (83.8%). 255 Teenager populations 257 A total of 24 children (from 3 to 11 years old) and 16 teenagers (from 12 Altogether, both populations found the procedures for both COVID-VIRO ® and COVID-VIRO 277 ALL IN ® easy or very easy to perform. Only 2 teenagers found the COVID-VIRO ® self-test 278 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our current study showed COVID-VIRO ALL IN ® present almost same 302 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.14.21263403 doi: medRxiv preprint performances with 93.02% sensitivity, 100% specificity and an overall agreement of 97,5% 303 with nasopharyngeal RT-PCR. 304 In addition to the performance assessment, we conducted a usability study following the FDA 305 recommendations. The participant was asked to read the test instructions and perform all 306 the procedures while being supervised, in order to assess whether the participant was able 307 to correctly perform the test on his/her own and interpret it accurately. This time, 68 adults of 308 different age, education level and socio-economic background, were included in the study 309 constituting a representative sampling of the French general population. According to them, 310 the quality of written instructions is good enough to be easily understood, proving that the 311 documents provided with the COVID-VIRO ALL IN ® test are accessible for all laypersons. 312 Moreover, this study showed that the COVID-VIRO ALL IN ® test is very practicable since all 313 participants were able to obtain a valid and interpretable result without requesting the 314 supervisor's assistance. 315 In terms of satisfaction about COVID-VIRO ALL IN ® usage, all the participants declared that 316 the sample collection or the subsequent testing procedures were easy or very easy to 317 perform, except one. Similarly, only one participant found the reading and the interpretation 318 steps somewhat difficult. All together, these results demonstrate that the COVID-VIRO ALL 319 IN ® test is highly adapted for use by an adult layperson. 320 Similar usability study was conducted on a population of 40 children (24 between 3 and 11 321 years old and 16 teenagers between 12 to 15 years old), while comparing directly COVID-322 VIRO ALL IN ® and COVID-VIRO ® first generation usage satisfaction. When asked which test 323 they preferred, most of them (83%) answered COVID-VIRO ALL IN ® because it is "easier", 324 "simpler" or "more comfortable". As such, the new COVID-VIRO ALL IN ® self-test allows a 325 high accurate diagnostic as good as first generation COVID-VIRO ® , but with better usability 326 and participant satisfaction. 327 Following our previous study, it seems that the usability of a COVID self-test is improved with 328 COVID-VIRO ALL IN ® for all types of population and especially for children, by combining all 329 components into one easy-to-use self-device, while maintaining high performance of the test. 330 As a RADT, it is a great alternative since it lowers the risks and adverse effects of nasal 331 classic swabs actually used with COVID self-tests. The sampling device seems indeed well 332 adapted for use by young children under adult supervision. The current French school 333 screening strategy for young children is based on the RT-PCR test done on saliva. This 334 matrix is known to be less sensitive than the nasopharyngeal sample that remains the 335 current gold standard. 8 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.14.21263403 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.14.21263403 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.14.21263403 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted September 26, 2021. ; https://doi.org/10.1101/2021.09.14.21263403 doi: medRxiv preprint World Health Organization. the media briefing on COVID-19 The epidemiology and pathogenesis of coronavirus disease 368 (COVID-19) outbreak Covid-19: which samples for which tests? Cerebrospinal Fluid Leak After Nasal Swab 373 Testing for Coronavirus Disease Meningitis due to cerebrospinal fluid leak after nasal swab testing for 377 COVID-19 Complications of nasal and pharyngeal swabs: a 379 relevant challenge of the COVID-19 pandemic? Saliva: Both a Threat and an Opportunity in Covid-19 Méta-analyse de l'intérêt diagnostique des tests RT-PCR salivaires de détection 383 du SARS-CoV-2 Considerations on the use of self-tests for COVID-19 in 385 the EU/EEA Food and Drug Administration. FDA Continues to Advance Over-the Counter and Other 392 Screening Test Development Covid-19 : quelle place pour les tests antigéniques nasaux 395 dans la stratégie de dépistage ? Avis SFM du 25/09/2020 relatif à l'interprétation de 399 la valeur de Ct (estimation de la charge virale) -Version 4 du 14/01/2021Avis du 25 400 septembre 2020 de la Société Française de Microbiologie (SFM) relatif à l'interprétation 401 de la valeur de Ct obtenue en cas de RT-PCR SARS-CoV-2 positive sur les 402 prélèvements cliniques réalisés à des fins diagnostiques ou de dépistage Evaluation of a SARS-CoV-2 antigen-detecting 404 rapid diagnostic test as a self-test: Diagnostic performance and usability SARS-CoV-2 antigen-detecting rapid diagnostic tests: An 408 implementation guide Template for Manufacturers of Molecular and Antigen 411 Diagnostic COVID-19 Tests for Non-Laboratory Use Self-testing and vaccination against 414 COVID-19 to minimize school closure All rights reserved. No reuse allowed without permission preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity